Peptidi

EDDnp is a potent and selective inhibitor of the proteolytic enzyme dipeptidyl peptidase IV (DPP-IV). EDDnp binds to the active site of DPP-IV, which prevents it from cleaving peptides at the carboxy terminus. The inhibition of DPP-IV results in an increase of peptide hormones such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), which are involved in regulating blood glucose levels. In addition, there are high values of EDDnp in human serum and urine, which may be due to its function as a potential biomarker for diabetes. The physiological function of EDDnp is still being investigated.

Hypertension is a common condition that affects millions of people worldwide. It is characterized by an elevated blood pressure and the subsequent damage to the heart, kidneys, and other tissues. Metyrapone is a drug that inhibits the synthesis of corticosteroids from cholesterol in the adrenal glands. It was shown to reduce blood pressure in vivo by blocking the formation of cytosolic calcium and subsequent release of vasopressin. The use of metyrapone as a hypertension treatment has been limited due to its side effects on the liver. A new model system using basic fibroblasts (BF) instead of liver cells has been developed to study this drug's effects on hypertension without causing liver lesions. This model has proven successful for other drugs with similar biological properties, such as Hytrinol, which also blocks corticosteroid synthesis from cholesterol but does not cause liver lesions. The BF system can be used for testing new drugs that are selective for PAR1 receptors, which are

Uroguanylin (Human) product containing the disulfide bonds: Cys4-Cys12 and Cys7-Cys15 and avaialable in the trifluoroacetate salt form. Uroguanylin is a peptide hormone that is involved in the regulation of fluid and electrolyte balance in the body. It is produced in the intestinal tract, specifically in the lining of the small intestine and colon.
Uroguanylin belongs to a family of peptides that includes guanylin and the heat-stable enterotoxins (STs).These peptides all share a similar structure and function, as they bind to and activate the guanylate cyclase-C (GC-C) receptor in intestinal cells.
Activation of GC-C by uroguanylin leads to an increase in cyclic GMP (cGMP) levels, which in turn activates a variety of downstream signaling pathways. This leads to an increase in chloride and bicarbonate secretion in the intestine, as well as an increase in intestinal fluid secretion. Uroguanylin also stimulates sodium and water reabsorption in the kidneys, leading to an increase in urine output.
Uroguanylin has been studied for its potential therapeutic applications, particularly in the treatment of gastrointestinal disorders. For example, synthetic analogs of uroguanylin are being developed as potential treatments for constipation and other disorders of intestinal motility. Additionally, uroguanylin has been shown to have anti-inflammatory properties and may be useful in the treatment of inflammatory bowel disease.

Peptide H-TLQALEFHTVPFQLLAR^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

Peptide LCBiot-PKYVKQNTLKLAT-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.